Actualidad

/
/
Masimo Announces Recent Study Monitoring Methemoglobin Levels During Administration of Inhaled Nitric Oxide

Masimo Announces Recent Study Monitoring Methemoglobin Levels During Administration of Inhaled Nitric Oxide

21/02/2017

IRVINE, Calif.–(BUSINESS WIRE)–Feb. 21, 2017–
Masimo (NASDAQ:
MASI) announced today the findings of a recent study conducted on
children admitted to a Ugandan hospital with fever and malaria, in which
Masimo’s noninvasive measurement SpMet® was used to monitor
methemoglobin (MetHb) levels. One group of children with severe malaria
was selected to receive inhaled nitric oxide (iNO) treatment as an
adjunct to intravenous therapy while a placebo group received room air.
Both of these groups were monitored with SpMet.1

Red blood cells containing hemoglobin can become oxidized in the
presence of certain drugs and com…

Más información: Masimo Announces Recent Study Monitoring Methemoglobin Levels During Administration of Inhaled Nitric Oxide

Comparte:

El contenido de este sitio web está destinado únicamente a profesionales médicos/sanitarios.

Es posible que los productos contenidos en este sitio no estén disponibles en todos los mercados, ya que la disponibilidad está sujeta a prácticas normativas y médicas en mercados individuales.